MA27643A1 - Utilisation de n-alkyl-4-methyleneamino-3-hydroxy-2-pyridones en tant qu'agents antimicrobiens - Google Patents

Utilisation de n-alkyl-4-methyleneamino-3-hydroxy-2-pyridones en tant qu'agents antimicrobiens

Info

Publication number
MA27643A1
MA27643A1 MA28269A MA28269A MA27643A1 MA 27643 A1 MA27643 A1 MA 27643A1 MA 28269 A MA28269 A MA 28269A MA 28269 A MA28269 A MA 28269A MA 27643 A1 MA27643 A1 MA 27643A1
Authority
MA
Morocco
Prior art keywords
methyleneamino
pyridones
hydroxy
alkyl
antimicrobial agents
Prior art date
Application number
MA28269A
Other languages
English (en)
Inventor
Namal Chithranga Warshakoon
Rodney Dean Bush
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA27643A1 publication Critical patent/MA27643A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention se rapporte à des composés représentés par la formuie (I), qui sont permettent de traiter efficacement des infections microbiennes
MA28269A 2002-11-09 2005-05-09 Utilisation de n-alkyl-4-methyleneamino-3-hydroxy-2-pyridones en tant qu'agents antimicrobiens MA27643A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42507002P 2002-11-09 2002-11-09

Publications (1)

Publication Number Publication Date
MA27643A1 true MA27643A1 (fr) 2005-12-01

Family

ID=32312926

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28269A MA27643A1 (fr) 2002-11-09 2005-05-09 Utilisation de n-alkyl-4-methyleneamino-3-hydroxy-2-pyridones en tant qu'agents antimicrobiens

Country Status (26)

Country Link
US (5) US6930117B2 (fr)
EP (1) EP1558579B1 (fr)
JP (1) JP4496083B2 (fr)
KR (2) KR20050055792A (fr)
CN (1) CN1708481A (fr)
AT (1) ATE372985T1 (fr)
AU (1) AU2003291382B2 (fr)
BR (1) BR0316107A (fr)
CA (1) CA2502264C (fr)
CO (1) CO5570678A2 (fr)
CY (1) CY1106958T1 (fr)
DE (1) DE60316338T2 (fr)
DK (1) DK1558579T3 (fr)
EG (1) EG25017A (fr)
ES (1) ES2293036T3 (fr)
HR (1) HRP20050516B1 (fr)
IL (1) IL168119A (fr)
MA (1) MA27643A1 (fr)
MX (1) MXPA05004896A (fr)
NO (1) NO330810B1 (fr)
NZ (1) NZ539386A (fr)
PL (1) PL377226A1 (fr)
PT (1) PT1558579E (fr)
RU (1) RU2311410C2 (fr)
WO (1) WO2004043927A1 (fr)
ZA (1) ZA200503683B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6930117B2 (en) * 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
BRPI0608907A2 (pt) 2005-05-10 2010-02-17 Itermune Inc método de modulação de sistema de proteìna cinase ativada por estresse
US7973060B2 (en) * 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CA2697399C (fr) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-(aryl-x-phenyl)-1h-pyridine-2-ones 1,3-disubstituees
CA2698929C (fr) 2007-09-14 2016-01-19 Addex Pharma S.A. 4-phenyle-1h-pyridine-2-ones 1,3-disubstituees
RS51660B (en) 2007-09-14 2011-10-31 Ortho-Mcneil-Janssen Pharmaceuticals Inc. 1`, 3`-DISUPSTITUATED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1`H- [1,4`] BIPYRIDINYL-2`-ONE
JP5433582B2 (ja) 2007-11-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． イミダゾ［１，２−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
WO2010025890A1 (fr) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Dérivés de 3-azabicyclo[3.1.0]hexyle comme modulateurs des récepteurs métabotropiques du glutamate
EP2346505B1 (fr) 2008-10-16 2014-04-23 Janssen Pharmaceuticals, Inc. DÉRIVÉS D'INDOLE ET DE BENZOMORPHOLINE EN TANT QUE MODULATEURS DE RÉCEPTEURS MÉTABOTROPIQUEs DU GLUTAMATE
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
EP2430022B1 (fr) 2009-05-12 2013-11-20 Janssen Pharmaceuticals, Inc. Dérivés de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation dans le traitement ou la prévention de maladies neurologiques ou psychiatriques
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2430031B1 (fr) 2009-05-12 2013-04-17 Janssen Pharmaceuticals, Inc. Dérivés de 1,2,4-triazolo [4,3-A]pyridine et leur utilisation en tant que modulateurs allostériques positifs de récepteurs mGluR2
CN102365024A (zh) 2009-07-06 2012-02-29 阿克比治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法
WO2011057112A1 (fr) * 2009-11-06 2011-05-12 Akebia Therapeutics Inc. Procédés pour augmenter la stabilisation du facteur inductible par l'hypoxie 1-alpha
HUE036431T2 (hu) 2010-03-04 2018-07-30 Merck Sharp & Dohme Katechin o-metil transzferáz gátlók és alkalmazásuk pszichotikus betegségek kezelésében
MX2012010188A (es) * 2010-03-04 2012-10-03 Merck Sharp & Dohme Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos.
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2012062750A1 (fr) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. Dérivés de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
EP2643320B1 (fr) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. Dérivés de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
WO2013056240A1 (fr) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Méthodes de traitement du syndrome de fuite vasculaire et du cancer
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
AU2014233363B2 (en) 2013-03-15 2017-06-29 EyePoint Pharmaceuticals, Inc. Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR20220038826A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
CN106232120B (zh) 2014-02-19 2021-01-08 爱尔皮奥治疗有限公司 制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
CA3026226A1 (fr) 2016-06-13 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Pyridines substituees en tant qu'inhibiteurs de dnmt1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US385390A (en) 1888-07-03 Sylvantjs l
US3852900A (en) * 1973-07-18 1974-12-10 J Svec Disc type indicia recording and display device
US3853900A (en) 1973-09-14 1974-12-10 Searle & Co 4-benzyloxy-2 (1h)-pyridones
DE2442714A1 (de) * 1974-09-06 1976-03-18 Benckiser Wassertechnik Joh A Verfahren und vorrichtung zum pumpen von fluessigkeiten mittels einer membrandosierpumpe
US5358949A (en) * 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
DE4316077A1 (de) * 1993-05-13 1994-11-17 Bayer Ag Substituierte Mono- und Bihydridylmethylpyridone
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5789426A (en) * 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US5849587A (en) * 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
JP4137636B2 (ja) 2000-12-28 2008-08-20 塩野義製薬株式会社 カンナビノイド２型受容体親和作用を有するピリドン誘導体
US6930117B2 (en) * 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
US6946479B2 (en) * 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones

Also Published As

Publication number Publication date
RU2005114489A (ru) 2005-11-20
HRP20050516B1 (hr) 2013-11-08
WO2004043927A1 (fr) 2004-05-27
US6930117B2 (en) 2005-08-16
AU2003291382B2 (en) 2008-07-31
KR20070026891A (ko) 2007-03-08
PT1558579E (pt) 2007-11-27
DK1558579T3 (da) 2008-01-14
EP1558579B1 (fr) 2007-09-12
CO5570678A2 (es) 2005-10-31
AU2003291382A1 (en) 2004-06-03
US20070270407A1 (en) 2007-11-22
BR0316107A (pt) 2005-09-27
US8133894B2 (en) 2012-03-13
CA2502264A1 (fr) 2004-05-27
DE60316338D1 (de) 2007-10-25
RU2311410C2 (ru) 2007-11-27
DE60316338T2 (de) 2008-06-05
KR100896675B1 (ko) 2009-05-08
NZ539386A (en) 2008-02-29
CY1106958T1 (el) 2012-09-26
CA2502264C (fr) 2009-12-15
US20040097560A1 (en) 2004-05-20
ZA200503683B (en) 2006-08-30
US20120115876A1 (en) 2012-05-10
US20050234045A1 (en) 2005-10-20
US7790748B2 (en) 2010-09-07
MXPA05004896A (es) 2005-07-22
ES2293036T3 (es) 2008-03-16
JP4496083B2 (ja) 2010-07-07
CN1708481A (zh) 2005-12-14
KR20050055792A (ko) 2005-06-13
ATE372985T1 (de) 2007-09-15
NO20052787D0 (no) 2005-06-09
EP1558579A1 (fr) 2005-08-03
HRP20050516A2 (en) 2005-12-31
US20100305097A1 (en) 2010-12-02
NO20052787L (no) 2005-06-09
PL377226A1 (pl) 2006-01-23
NO330810B1 (no) 2011-07-25
EG25017A (en) 2011-05-25
US7247648B2 (en) 2007-07-24
JP2006508133A (ja) 2006-03-09
IL168119A (en) 2011-11-30

Similar Documents

Publication Publication Date Title
MA27643A1 (fr) Utilisation de n-alkyl-4-methyleneamino-3-hydroxy-2-pyridones en tant qu'agents antimicrobiens
NO20052788L (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
ECSP003699A (es) Inhibidores de fab i
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
BR0116217A (pt) Quinolonas antimicrobianas, composição farmacêutica, bem como aplicação farmacêutica das referidas quinolonas
NO20062629L (no) Oksazolderivater av tetrackliner
ATE516022T1 (de) Antimikrobielle zusammensetzungen und anwendungsverfahren dafür
DK0920421T3 (da) Isoxazolinderivater anvendelige som antimikrobielle midler
DK1709044T3 (da) Oxazolidinon-quinolon-hybridantibiotika
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
BR0316085A (pt) Substâcias microbicidas
BR0010982A (pt) Novas oxazolidinonas bicìclicas como agentes antibacterianos
DK1305037T3 (da) Smertestillende medikament
ATE368025T1 (de) Pleuromutilinderivate mit antimikrobieller wirkung
MXPA06000372A (es) Compuestos de silicio y su uso.
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
ATE252573T1 (de) 2-aryloxy-4-methyl-6-pyrazol-1-yl-pyridine wirksam als herbizide
PT1140932E (pt) Derivados de 1,8-benzonaftiridina
ATE478155T1 (de) Glycopeptidantibiotika